Cargando…
Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches
Hepatitis B virus infection (HBV) is one of the most common causes of hepatitis, and may lead to cirrhosis or hepatocellular carcinoma. According to the World Health Organization (WHO), approximately 296 million people worldwide are carriers of the hepatitis B virus. Various nucleos(t)ide analogs, w...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836293/ https://www.ncbi.nlm.nih.gov/pubmed/35163539 http://dx.doi.org/10.3390/ijms23031617 |
_version_ | 1784649641904570368 |
---|---|
author | Sadiea, Rahila Zannat Sultana, Shahnaj Chaki, Bijan Mohon Islam, Tasnim Dash, Sharmy Akter, Sharmin Islam, Md Sayeedul Kazi, Taheruzzaman Nagata, Abir Spagnuolo, Rocco Mancina, Rosellina Margherita Hossain, Md Golzar |
author_facet | Sadiea, Rahila Zannat Sultana, Shahnaj Chaki, Bijan Mohon Islam, Tasnim Dash, Sharmy Akter, Sharmin Islam, Md Sayeedul Kazi, Taheruzzaman Nagata, Abir Spagnuolo, Rocco Mancina, Rosellina Margherita Hossain, Md Golzar |
author_sort | Sadiea, Rahila Zannat |
collection | PubMed |
description | Hepatitis B virus infection (HBV) is one of the most common causes of hepatitis, and may lead to cirrhosis or hepatocellular carcinoma. According to the World Health Organization (WHO), approximately 296 million people worldwide are carriers of the hepatitis B virus. Various nucleos(t)ide analogs, which specifically suppress viral replication, are the main treatment agents for HBV infection. However, the development of drug-resistant HBV strains due to viral genomic mutations in genes encoding the polymerase protein is a major obstacle to HBV treatment. In addition, adverse effects can occur in patients treated with nucleos(t)ide analogs. Thus, alternative anti-HBV drugs of plant origin are being investigated as they exhibit excellent safety profiles and have few or no side effects. In this study, phytomedicines/phytochemicals exerting significant inhibitory effects on HBV by interfering with its replication were reviewed based on different compound groups. In addition, the chemical structures of these compounds were developed. This will facilitate their commercial synthesis and further investigation of the molecular mechanisms underlying their effects. The limitations of compounds previously screened for their anti-HBV effect, as well as future approaches to anti-HBV research, have also been discussed. |
format | Online Article Text |
id | pubmed-8836293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88362932022-02-12 Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches Sadiea, Rahila Zannat Sultana, Shahnaj Chaki, Bijan Mohon Islam, Tasnim Dash, Sharmy Akter, Sharmin Islam, Md Sayeedul Kazi, Taheruzzaman Nagata, Abir Spagnuolo, Rocco Mancina, Rosellina Margherita Hossain, Md Golzar Int J Mol Sci Review Hepatitis B virus infection (HBV) is one of the most common causes of hepatitis, and may lead to cirrhosis or hepatocellular carcinoma. According to the World Health Organization (WHO), approximately 296 million people worldwide are carriers of the hepatitis B virus. Various nucleos(t)ide analogs, which specifically suppress viral replication, are the main treatment agents for HBV infection. However, the development of drug-resistant HBV strains due to viral genomic mutations in genes encoding the polymerase protein is a major obstacle to HBV treatment. In addition, adverse effects can occur in patients treated with nucleos(t)ide analogs. Thus, alternative anti-HBV drugs of plant origin are being investigated as they exhibit excellent safety profiles and have few or no side effects. In this study, phytomedicines/phytochemicals exerting significant inhibitory effects on HBV by interfering with its replication were reviewed based on different compound groups. In addition, the chemical structures of these compounds were developed. This will facilitate their commercial synthesis and further investigation of the molecular mechanisms underlying their effects. The limitations of compounds previously screened for their anti-HBV effect, as well as future approaches to anti-HBV research, have also been discussed. MDPI 2022-01-30 /pmc/articles/PMC8836293/ /pubmed/35163539 http://dx.doi.org/10.3390/ijms23031617 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sadiea, Rahila Zannat Sultana, Shahnaj Chaki, Bijan Mohon Islam, Tasnim Dash, Sharmy Akter, Sharmin Islam, Md Sayeedul Kazi, Taheruzzaman Nagata, Abir Spagnuolo, Rocco Mancina, Rosellina Margherita Hossain, Md Golzar Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches |
title | Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches |
title_full | Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches |
title_fullStr | Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches |
title_full_unstemmed | Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches |
title_short | Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches |
title_sort | phytomedicines to target hepatitis b virus dna replication: current limitations and future approaches |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836293/ https://www.ncbi.nlm.nih.gov/pubmed/35163539 http://dx.doi.org/10.3390/ijms23031617 |
work_keys_str_mv | AT sadiearahilazannat phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches AT sultanashahnaj phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches AT chakibijanmohon phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches AT islamtasnim phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches AT dashsharmy phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches AT aktersharmin phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches AT islammdsayeedul phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches AT kazitaheruzzaman phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches AT nagataabir phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches AT spagnuolorocco phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches AT mancinarosellinamargherita phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches AT hossainmdgolzar phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches |